GET HELP NOW

Monday, April 16, 2018

Combination therapy doubles survival in metastatic lung cancer

https://ift.tt/eA8V8J The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.

from https://ift.tt/2H4cBRg
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...